
IBM Watson for Oncology
AI Recommends Unsafe Cancer Treatments
MD Anderson Cancer Center partnered with IBM Watson to build an AI system for recommending cancer treatments.
- 01TRIGGERMD Anderson Cancer Center partnered with IBM Watson to build an AI system for recommending cancer treatments.
- 02MACHINE ACTIONMaterial contributor
- 03MISSING GATERisk-based SME approval before execution
- 04IMPACTHuman welfare
The short version
MD Anderson Cancer Center partnered with IBM Watson to build an AI system for recommending cancer treatments.
Case telemetry
- INCIDENT
- SS-IR-005
- DATE
- 2013-2017
- SYSTEM
- IBM Watson for Oncology
- LOCATION / SCOPE
- Houston, Texas, USA
- EVIDENCE
- Reported
- AI ROLE
- Material contributor
- HARM
- Human welfare
- SOURCES
- 1 cited record
The event
MD Anderson Cancer Center partnered with IBM Watson to build an AI system for recommending cancer treatments. After spending $62 million, internal audits revealed Watson for Oncology was recommending treatments that were unsafe and contradicted established oncology guidelines. In one documented case, Watson recommended giving a cancer patient with severe bleeding a drug that would worsen the bleeding. The system was trained primarily on synthetic cases created by a small group of doctors at Memorial Sloan Kettering, not on real patient outcomes.
What the machine did
Watson for Oncology was marketed as an AI that could process millions of medical papers and recommend evidence-based treatments. In reality, the system's recommendations were largely based on the opinions of a handful of MSK physicians encoded as training data. When deployed in hospitals across Asia and Latin America, Watson recommended treatments based on American insurance formularies that were unavailable or inappropriate in those countries.
Where the failure landed
$62 million spent by MD Anderson with no usable system delivered. The project was cancelled. Hospitals worldwide that had adopted Watson for Oncology found its recommendations unreliable. STAT News documented multiple instances of unsafe treatment suggestions. IBM eventually sold Watson Health for a fraction of its investment.
Reported
Documented in the cited public record. Follow the sources for the precise evidentiary posture.
SOURCE RECORD UPDATED 2026-07-09
1 cited record
- 01Secondary / analysisSTAT News: IBM Watson recommended unsafe and incorrect cancer treatments (2018)
Risk-based SME approval before execution
The failure pattern in this case: High-stakes output had no accountable checkpoint.
The moment the path could change
The appropriate subject-matter expert reviews the evidence, exceptions, and affected people before the output becomes action.
Autonomy is a design choice.
See the operating model that keeps AI useful while preserving human authority at consequential moments.
Compare AgenticAI and AugmentedAI →